Viking Therapeutics completes enrollment in its phase III VANQUISH-1 obesity study, surpassing targets and marking rapid ...

The emerging prevalence of digitalization is a key topic for manufacturers handling excipients. Digital transformation and data integrity protocols are crucial strategies for optimizing drug ...

FSSAI orders removal of non-compliant drinks falsely labelled as “ORS”, targeting deceptive marketing and protecting ...

Cash and cash equivalents totaled €119.0 million as of September 30, 2025€39.2 million in revenues for the nine months ended September 30, 2025, including the €26.5 million milestone payment following ...

United Therapeutics' stock surged after IPF trial results and what future pivotal trials could mean for investors. See here ...

FSSAI orders immediate removal of misleading electrolyte & ORS drinks from shelves & online. Protect yourself! Learn more ...

The regulatory board is demanding that all food business operators (FBOs) must stop using "ORS" in drinks unless the formula ...

Rafa Laboratories secured a BARDA contract to develop an intramuscular TXA injection for prehospital bleeding care.

F or Big Pharma, the triumph of developing a new lifesaving blockbuster drug that generates billions in revenue is inevitably ...

While the FDA is streamlining regulation of copycat versions of the expensive drugs that millions take for arthritis, cancer, and other diseases, the U.S. patent office is making it harder for the ...

VANCOUVER, BC / ACCESS Newswire / November 20, 2025 / Onco-Innovations Limited (CBOE CA:ONCO)(OTCQB:ONNVF)(Frankfurt:W1H, WKN:A3EKSZ) ("Onco" or the "Company") is pleased to announce that its manufact ...

Cash and cash equivalents totaled €119.0 million as of September 30, 2025€39.2 million in revenues for the nine months ended September 30, 2025, including the €26.5 million milestone payment following ...